Lokesh Chandak will replace the current Chief Financial Officer Amit Gupta

Procter & Gamble Health appoints Lokesh Chandak as CFO

Procter & Gamble Health shares had a robust gap up opening on Monday, rising nearly 15 percent to Rs 4,703, the highest closing level since February 16, 2022. In fact, the gap up opening has helped the stock climb over all long term moving averages (50, 100 and 200 EMA). The stock has formed strong …

Trade Spotlight | Your blueprint for Procter & Gamble Health, M&M Financial Services, Zydus Lifesciences today

Procter & Gamble Health reported a net profit of Rs 76.80 crore in the quarter that ended December 2022 (Q3 FY23), which is higher by 71.28 per cent as compared to Rs 44.84 crore in the same period last year.

Procter & Gamble Health shares surge 15% today amid heavy volumes

Procter & Gamble Health Ltd saw volume of 1.24 lakh shares by 14:14 IST on NSE, a 33 fold spurt over two-week average daily volume of 3766 shares

Volumes jump at Procter & Gamble Health Ltd counter

Procter & Gamble Health’s profitability was supported by improved margin through portfolio premiumisation, healthy mix and optimization of expenses.

Procter & Gamble Health shares spike 13% on 71% surge in profit

Indus Towers Ltd, Procter & Gamble Health Ltd, Zydus Lifesciences Ltd and Mahindra & Mahindra Financial Services Ltd are among the other gainers in the BSE’s ‘A’ group today, 06 February 2023.

Vodafone Idea Ltd leads gainers in ‘A’ group

Procter & Gamble Health Ltd notched up volume of 3110 shares by 10:47 IST on BSE, a 7.57 fold spurt over two-week average daily volume of 411 shares

Volumes spurt at Procter & Gamble Health Ltd counter

Procter & Gamble Health zoomed 12% to Rs 4588.70 after the company reported a net profit of Rs 76.8 crore in the quarter ended 31 December 2022, which is higher by _ % as compared with a PAT of Rs 44.9 crore in the same period last year.

Procter & Gamble Health soars after strong December quarter performance

One of India’s leading VMS companies, Procter & Gamble Health Limited produces and markets vitamins, minerals, and supplements for healthcare.

Pharma stock declares ₹45 interim dividend, posts 71% net profit growth in Q3

Dalmia Bharat, JK Cement, Birla Corp., and Procter & Gamble Health will announce their quarterly results this weekend.

Dalmia Cement, JK Cement, Birla Corp, Finolex, Rossario Biotech Q3 Results — Earnings Estimates

Procter & Gamble Health Ltd recorded volume of 1419 shares by 10:45 IST on BSE, a 4.33 times surge over two-week average daily volume of 328 shares

Volumes soar at Procter & Gamble Health Ltd counter

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced and in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Not a good time to consider, stock is in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Procter & Gamble Health Limited, formerly Merck Limited, is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments